



SOME CHEMICALS  
THAT CAUSE TUMOURS  
OF THE URINARY TRACT  
IN RODENTS

VOLUME 119

This publication represents the views and expert  
opinions of an IARC Working Group on the  
Evaluation of Carcinogenic Risks to Humans,  
which met in Lyon, 6–13 June 2017

LYON, FRANCE - 2019

IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC RISKS  
TO HUMANS

# CONTENTS

---

NOTE TO THE READER .....	1
LIST OF PARTICIPANTS .....	3
<b>PREAMBLE .....</b>	<b>9</b>
A. GENERAL PRINCIPLES AND PROCEDURES .....	9
1. Background .....	9
2. Objective and scope .....	10
3. Selection of agents for review .....	11
4. Data for the <i>Monographs</i> .....	12
5. Meeting participants .....	12
6. Working procedures .....	13
B. SCIENTIFIC REVIEW AND EVALUATION .....	14
1. Exposure data .....	15
2. Studies of cancer in humans .....	16
3. Studies of cancer in experimental animals .....	20
4. Mechanistic and other relevant data .....	23
5. Summary .....	26
6. Evaluation and rationale .....	27
References .....	31
<b>GENERAL REMARKS .....</b>	<b>33</b>
<b>1-TERT-BUTOXYPROPAN-2-OL .....</b>	<b>37</b>
1. Exposure Data .....	37
1.1 Identification of the agent .....	37
1.2 Production and use .....	37
1.3 Analytical methods .....	38
1.4 Occurrence and exposure .....	38
1.5 Regulations and guidelines .....	39
2. Cancer in Humans .....	39

---

3. Cancer in Experimental Animals .....	39
3.1 Mouse .....	39
3.2 Rat .....	43
4. Mechanistic and Other Relevant Data .....	44
4.1 Absorption, distribution, metabolism, and excretion .....	44
4.2 Mechanisms of carcinogenesis .....	45
4.3 Data relevant to comparisons across agents and end-points .....	45
4.4 Susceptibility to cancer .....	48
4.5 Other adverse effects .....	48
5. Summary of Data Reported .....	49
5.1 Exposure data .....	49
5.2 Human carcinogenicity data .....	49
5.3 Animal carcinogenicity data .....	49
5.4 Mechanistic and other relevant data .....	50
6. Evaluation .....	50
6.1 Cancer in humans .....	50
6.2 Cancer in experimental animals .....	50
6.3 Overall evaluation .....	50
References .....	50
 <b>β-MYRCENE .....</b>	 <b>53</b>
1. Exposure Data .....	53
1.1 Identification of the agent .....	53
1.2 Production and use .....	54
1.3 Analytical methods .....	55
1.4 Occurrence and exposure .....	55
1.5 Regulations and guidelines .....	61
2. Cancer in Humans .....	63
3. Cancer in Experimental Animals .....	63
3.1 Oral administration .....	63
3.2 Co-carcinogenicity studies .....	68
4. Mechanistic and Other Relevant Data .....	68
4.1 Absorption, distribution, metabolism, and excretion .....	68
4.2 Mechanisms of carcinogenesis .....	70
4.3 Data relevant to comparisons across agents and end-points .....	73
4.4 Susceptibility to cancer .....	73
4.5 Other adverse effects .....	73
5. Summary of Data Reported .....	74
5.1 Exposure data .....	74
5.2 Human carcinogenicity data .....	74
5.3 Animal carcinogenicity data .....	74
5.4 Mechanistic and other relevant data .....	75
6. Evaluation .....	75
6.1 Cancer in humans .....	75
6.2 Cancer in experimental animals .....	75

---

6.3 Overall evaluation .....	75
References .....	75
<b>FURFURYL ALCOHOL .....</b>	<b>83</b>
1. Exposure Data.....	83
1.1 Identification of the agent .....	83
1.2 Production and use.....	84
1.3 Analytical methods .....	85
1.4 Occurrence and exposure.....	85
1.5 Regulations and guidelines .....	91
2. Cancer in Humans .....	93
3. Cancer in Experimental Animals .....	93
3.1 Mouse.....	93
3.2 Rat .....	93
3.3 Transgenic animals.....	97
4. Mechanistic and Other Relevant Data .....	98
4.1 Absorption, distribution, metabolism, and excretion .....	98
4.2 Mechanisms of carcinogenesis.....	100
4.3 Data relevant to comparisons across agents and end-points .....	105
4.4 Susceptibility to cancer.....	105
4.5 Other adverse effects .....	105
5. Summary of Data Reported .....	105
5.1 Exposure data.....	105
5.2 Human carcinogenicity data.....	106
5.3 Animal carcinogenicity data.....	106
5.4 Mechanistic and other relevant data.....	106
6. Evaluation.....	107
6.1 Cancer in humans .....	107
6.2 Cancer in experimental animals.....	107
6.3 Overall evaluation .....	107
References .....	107
<b>MELAMINE .....</b>	<b>115</b>
1. Exposure Data.....	115
1.1 Identification of the agent .....	115
1.2 Production and use.....	116
1.3 Analytical methods .....	117
1.4 Occurrence and exposure .....	117
1.5 Regulations and guidelines .....	131
2. Cancer in Humans .....	132
3. Cancer in Experimental Animals .....	133
3.1 Mouse .....	133
3.2 Rat .....	140
4. Mechanistic and Other Relevant Data .....	142
4.1 Absorption, distribution, metabolism, and excretion .....	142
4.2 Mechanisms of carcinogenesis.....	146

---

4.3 Data relevant to comparisons across agents and end-points .....	153
4.4 Susceptibility to cancer .....	154
4.5 Other adverse effects .....	154
5. Summary of Data Reported .....	158
5.1 Exposure data .....	158
5.2 Human carcinogenicity data .....	158
5.3 Animal carcinogenicity data .....	159
5.4 Mechanistic and other relevant data .....	159
6. Evaluation .....	160
6.1 Cancer in humans .....	160
6.2 Cancer in experimental animals .....	160
6.3 Overall evaluation .....	160
References .....	160
 <b>PYRIDINE .....</b>	 <b>173</b>
1. Exposure Data .....	173
1.1 Identification of the agent .....	173
1.2 Production and use .....	174
1.3 Analytical methods .....	175
1.4 Occurrence and exposure .....	175
1.5 Regulations and guidelines .....	178
2. Cancer in Humans .....	180
3. Cancer in Experimental Animals .....	180
3.1 Mouse .....	180
3.2 Rat .....	186
4. Mechanistic and Other Relevant Data .....	188
4.1 Absorption, distribution, metabolism, and excretion .....	188
4.2 Mechanisms of carcinogenesis .....	191
4.3 Data relevant to comparisons across agents and end-points .....	196
4.4 Susceptibility to cancer .....	196
4.5 Other adverse effects .....	196
5. Summary of Data Reported .....	196
5.1 Exposure data .....	196
5.2 Human carcinogenicity data .....	197
5.3 Animal carcinogenicity data .....	197
5.4 Mechanistic and other relevant data .....	197
6. Evaluation .....	198
6.1 Cancer in humans .....	198
6.2 Cancer in experimental animals .....	198
6.3 Overall evaluation .....	198
References .....	198

---

<b>TETRAHYDROFURAN .....</b>	<b>205</b>
1. Exposure Data .....	205
1.1 Identification of the agent .....	205
1.2 Production and use .....	206
1.3 Analytical methods .....	206
1.4 Occurrence and exposure .....	208
1.5 Regulations and guidelines .....	209
2. Cancer in Humans .....	211
3. Cancer in Experimental Animals .....	211
3.1 Mouse .....	211
3.2 Rat .....	214
4. Mechanistic and Other Relevant Data .....	215
4.1 Absorption, distribution, metabolism, and excretion .....	215
4.2 Mechanisms of carcinogenesis .....	216
4.3 Data relevant to comparisons across agents and end-points .....	218
4.4 Susceptibility to cancer .....	218
4.5 Other adverse effects .....	218
5. Summary of Data Reported .....	219
5.1 Exposure data .....	219
5.2 Human carcinogenicity data .....	219
5.3 Animal carcinogenicity data .....	219
5.4 Mechanistic and other relevant data .....	220
6. Evaluation .....	220
6.1 Cancer in humans .....	220
6.2 Cancer in experimental animals .....	220
6.3 Overall evaluation .....	220
References .....	220
<b>VINYLDENE CHLORIDE .....</b>	<b>225</b>
1. Exposure Data .....	225
1.1 Identification of the agent .....	225
1.2 Production and use .....	226
1.3 Analytical methods .....	227
1.4 Occurrence and exposure .....	227
1.5 Regulations and guidelines .....	231
2. Cancer in Humans .....	233
3. Cancer in Experimental Animals .....	233
3.1 Mouse .....	233
3.2 Rat .....	245
3.3 Hamster .....	248
4. Mechanistic and Other Relevant Data .....	248
4.1 Absorption, distribution, metabolism, and excretion .....	248
4.2 Mechanisms of carcinogenesis .....	251
4.3 Data relevant to comparisons across agents and end-points .....	259
4.4 Susceptibility to cancer .....	259
4.5 Other adverse effects .....	259

5. Summary of Data Reported .....	260
5.1 Exposure data.....	260
5.2 Human carcinogenicity data.....	260
5.3 Animal carcinogenicity data.....	260
5.4 Mechanistic and other relevant data.....	261
6. Evaluation.....	262
6.1 Cancer in humans .....	262
6.2 Cancer in experimental animals.....	262
6.3 Overall evaluation .....	262
6.4 Rationale .....	262
References. ....	263
<b>LIST OF ABBREVIATIONS .....</b>	<b>271</b>
<b>ANNEX 1. SUPPLEMENTAL MATERIAL .....</b>	<b>273</b>